• Bestatin Enhances Endothelial Invasion in Fibrin: Mechanisti

  2026-04-20

  This study reveals that bestatin, an aminopeptidase inhibitor, unexpectedly stimulates microvascular endothelial cell invasion and capillary-like tube formation within a fibrin matrix. These findings challenge previous assumptions about bestatin’s anti-angiogenic activity and highlight the complexity of proteolytic regulation in angiogenesis, with implications for tumor biology and the design of anti-angiogenic therapies.

• Peptidisc-Assisted Nanobody Multimerization: Method and Impa

  2026-04-20

  Chen and Duong van Hoa introduce a peptidisc-based method to cluster nanobodies via hydrophobic interactions, enabling stable, multimeric, and multispecific protein assemblies. This approach enhances affinity and functional versatility, offering a generalizable strategy for protein engineering and detection workflows.

• 8-Chloroadenosine: Transforming Non-Coding RNA Cancer Resear

  2026-04-19

  This thought-leadership article explores the mechanistic and strategic value of 8-Chloroadenosine—a high-purity nucleoside analog from APExBIO—in driving innovation at the intersection of transcriptional regulation and non-coding RNA-mediated cancer biology. Building on recent breakthroughs in NSCLC, we offer actionable guidance for translational researchers seeking robust, reproducible, and mechanistically sound solutions for RNA metabolism and therapeutic discovery.

• BRD4770 (SKU B4837): A Reliable G9a Inhibitor for Robust Epi

  2026-04-18

  This article delivers a scenario-driven, evidence-based guide for employing BRD4770 (SKU B4837) as a G9a histone methyltransferase inhibitor in cancer biology research. By addressing real-world laboratory challenges, we demonstrate how BRD4770 from APExBIO provides consistent, data-backed solutions for cell viability, proliferation, and cytotoxicity assays, supporting reproducible and insightful epigenetic investigations.

• Omeprazole (A2845): Technical Guidance for Gastric Acid Rese

  2026-04-17

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor widely used for investigating gastric acid secretion mechanisms and antiulcer activity in preclinical research. It is optimized for reproducible results in cell-based and biochemical assays targeting proton pump function. This product is unsuitable for diagnostic or clinical use and is limited to controlled laboratory workflows.

• JZL184: Precision Monoacylglycerol Lipase Inhibitor Workflow

  2026-04-16

  JZL184, from APExBIO, is a potent monoacylglycerol lipase inhibitor that empowers researchers to dissect endocannabinoid signaling and CB1-mediated pathways with unmatched specificity. This article details optimized experimental workflows, highlights translational use-cases in neuropharmacology and pain models, and provides troubleshooting strategies for reproducible, high-impact data.

• EPO-BM-MSCs Enhance Mitochondrial Transfer to Alleviate Asth

  2026-04-15

  Zhang et al. demonstrate that erythropoietin-modified bone marrow mesenchymal stem cells (EPO-BM-MSCs) significantly attenuate airway inflammation in asthma by enhancing mitochondrial transfer to epithelial cells via upregulation of HO-1. This study provides mechanistic insight into cell-based therapies targeting mitochondrial dysfunction in chronic airway diseases.

• AZD3463: Transforming ALK/IGF1R Inhibition in Neuroblastoma

  2026-04-14

  This thought-leadership article explores the mechanistic depth and translational strategy of AZD-3463, a next-generation ALK/IGF1R inhibitor, for neuroblastoma research. Integrating evidence-based protocol guidance, comparative analysis, and a nuanced outlook, it provides actionable insights for researchers aiming to optimize ALK-mediated PI3K/AKT/mTOR pathway inhibition and drive precision oncology forward.

• STAT2 Coiled-Coil Degron: Mechanisms of Zika Virus Immune Ev

  2026-04-13

  Parisien et al. identify a specific degron within the human STAT2 coiled-coil domain essential for Zika virus NS5-mediated degradation, clarifying how Zika suppresses interferon signaling. This mechanistic insight reveals new antiviral targets and illustrates the utility of modular protein domains in dissecting host-pathogen interactions.

• Gap19: Selective Connexin 43 Hemichannel Blocker in Neuropro

  2026-04-12

  Gap19 is a highly selective connexin 43 hemichannel blocker, enabling precise inhibition of neuroglial ATP release and robust neuroprotection in cerebral ischemia models. This article dissects applied workflows, protocol optimization, and troubleshooting for maximal research impact with Gap19.

• Efficient Purification of Recombinant Annexin V for Biophysi

  2026-04-12

  This study introduces a rapid and effective protocol for purifying recombinant annexin V, enabling detailed biophysical analyses of its calcium-dependent membrane binding and ion channel activity. The method's main advance is the combination of mild bacterial cell lysis and calcium-mediated affinity steps, yielding highly pure protein essential for structural and electrophysiological studies.

• Z-VDVAD-FMK: Precision Caspase-2 Inhibition in Apoptosis Ass

  2026-04-11

  Z-VDVAD-FMK empowers researchers to dissect mitochondrial and caspase-driven apoptotic pathways with high specificity and robust protocol support. Its cell-permeable, irreversible mechanism uniquely supports advanced apoptosis assay design, caspase activity measurement, and mechanistic cancer research.

• Applied Workflows with (-)-Epigallocatechin Gallate (EGCG)

  2026-04-11

  Unlock the full potential of (-)-Epigallocatechin gallate (EGCG) in advanced apoptosis and inflammation models with evidence-based, workflow-optimized protocols. This article bridges recent hydrogel-based delivery innovations with practical troubleshooting and comparative insights for cancer chemoprevention and antiviral research.

• Gepotidacin: Novel Triazaacenaphthylene Bacterial Type II...

  2026-04-10

  Gepotidacin is a first-in-class triazaacenaphthylene antibiotic that selectively inhibits bacterial type II topoisomerases, offering potent activity against multidrug-resistant pathogens. Its unique mechanism and robust pharmacokinetic profile make it a leading tool for antibacterial research and antibiotic resistance studies.

• Gepotidacin (BA1220): A First-in-Class Bacterial Type II ...

  2026-04-09

  Gepotidacin is a novel triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor, offering potent, broad-spectrum activity against multidrug-resistant pathogens. Its unique mechanism disrupts DNA gyrase and topoisomerase IV, making it a valuable tool in antibacterial research and antibiotic resistance studies.

407 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page